UDG Healthcare (OTCMKTS:UDHCF) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Wednesday.
Separately, Zacks Investment Research raised UDG Healthcare from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research report on Friday, January 12th.
Shares of UDHCF opened at $12.48 on Wednesday. UDG Healthcare has a one year low of $10.85 and a one year high of $12.95.
About UDG Healthcare
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services to the healthcare industry in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates through three segments: Ashfield, Sharp, and Aquilant.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for UDG Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UDG Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.